NEUMED

HT042 is a standardized complex natural product ingredient developed from Astragalus, Eleuthero, and Phlomis root. It has been recognized by the MFDS for the functionality of “may help support children’s height growth.” NeuMed has studied children’s height growth not simply as a matter of nutritional supplementation, but from the perspective of growth plate function and developmental physiology. HT042 has been evaluated for both growth-related and safety-related indicators through two human studies. In addition to MFDS recognition in Korea, HT042 received a No Objection response through the U.S. FDA New Dietary Ingredient notification process and was selected as a WHO H2I Global Top 21 innovation among 1,175 submissions worldwide at WHO Health & Heritage Innovations 2025, where it was introduced as a heritage-based growth science case.

HT042 is a standardized complex natural product ingredient developed from Astragalus, Eleuthero, and Phlomis root. It has been recognized by the MFDS for the functionality of “may help support children’s height growth.” NeuMed has studied children’s height growth not simply as a matter of nutritional supplementation, but from the perspective of growth plate function and developmental physiology.

HT042 has been evaluated for both growth-related and safety-related indicators through two human studies. In addition to MFDS recognition in Korea, HT042 received a No Objection response through the U.S. FDA New Dietary Ingredient notification process and was selected as a WHO H2I Global Top 21 innovation among 1,175 submissions worldwide at WHO Health & Heritage Innovations 2025, where it was introduced as a heritage-based growth science case.

Some children may grow more slowly than their peers even when they receive adequate nutrition.
In such cases, growth may not be explained by nutrition alone.

Height growth is influenced by a complex growth-regulating system involving the brain, liver, and growth plate.
If this system does not respond properly, a child’s growth pace may slow down even when nutritional intake is sufficient.

The growth plate gradually begins to close from early puberty.
Once the growth plate is closed, height growth becomes difficult to change.
This is why children’s growth requires attention not only to nutrition,
but also to the growth environment and growth plate function.

Some children may grow more slowly than their peers even when they receive adequate nutrition. In such cases, growth may not be explained by nutrition alone. Height growth is influenced by a complex growth-regulating system involving the brain, liver, and growth plate. If this system does not respond properly, a child’s growth pace may slow down even when nutritional intake is sufficient. The growth plate gradually begins to close from early puberty. Once the growth plate is closed, height growth becomes difficult to change. This is why children’s growth requires attention not only to nutrition, but also to the growth environment and growth plate function.

More

PARENTS AND GUARDIANS

FOR PARENTS CONCERNED ABOUT THEIR CHILD’S GROWTH PACE

Growth Support Evaluated in Human Studies

HT042 was evaluated in two human studies involving children, with growth-related indicators assessed in comparison with placebo.

Hormone-Related Safety Indicators Reviewed

In the studies, sex hormone levels and bone age progression were monitored, with no significant differences observed compared with placebo.

Growth Plate and Bone-Related Indicators Studied

HT042 has been studied from the perspective of growth plate function, bone length growth, and growth-related biomarkers.

No Serious Adverse
Events Reported

In the 24-week study, no serious adverse events were attributed to HT042, and reported side effects were mild and comparable with placebo.

B2B PARTNERS AND BRANDS

FOR HEALTH FUNCTIONAL FOOD BRANDS SEEKING A DIFFERENTIATED CHILDREN'S GROWTH INGREDIENT

Built on Long-Term
Growth Research

HT042 is based on growth research that began in 1999 at Kyung Hee University College of Korean Medicine and has continued through preclinical research, human studies, ingredient standardization, and quality assurance.

No. 1 in Sales
for 11 Consecutive Years

HT042 has been Korea’s No. 1 selling children’s growth ingredient for 11 consecutive years, supporting strong market recognition and consumer trust.

Scientific Data Available
for Partners

Partners can access scientific and technical materials, including human study data, research publications, patents, and quality documentation.

Global Review
and Recognition History

HT042 has received a U.S. FDA NDI No Objection response and was selected as a WHO H2I Global Top 21 innovation, supporting its potential for global market expansion.

HT042 is NeuMed’s botanical complex extract developed from Astragalus, Eleuthero, and Phlomis. Based on the NeuQure™ Botanical Quality Assurance System, NeuMed manages the botanical origin, production region, cultivation environment, extraction process, and marker compounds of the source plants to ensure consistent quality for HT042. Astragalus and Eleuthero are cultivated and managed in an organic cultivation area near the Baekdu Mountain region. From raw material intake to extraction, concentration, drying, and finished ingredient specifications, each stage is managed according to NeuMed’s stepwise quality standards.

VITALITY AND GROWTH

ASTRAGALUS

Traditional Records

Astragalus is a medicinal herb with a long history of traditional use. It appears in historical records such as the Annals of the Joseon Dynasty as a tonic material used for the crown prince. Donguibogam describes it as an herb that supports energy and physical nourishment, and the Compendium of Materia Medica refers to it as a leading tonic herb.

Modern Research

In cell and animal studies, astragaloside IV, a key component of Astragalus, has been studied in relation to genes involved in growth hormone secretion and IGF-1 production in the liver.

More

PARENTS AND GUARDIANS

FOR PARENTS CONCERNED
ABOUT THEIR CHILD’S
GROWTH PACE

Growth Support Evaluated
in Human Studies

HT042 was evaluated in two human studies involving children,
with growth-related indicators assessed
in comparison with placebo.

Hormone-Related Safety
Indicators Reviewed

In the studies, sex hormone levels and bone age progression were monitored,
with no significant differences observed compared with placebo.

Growth Plate and Bone-Related
Indicators Studied

HT042 has been studied from the perspective of growth plate function,
bone length growth, and growth-related biomarkers.